Abstract: The disclosure relates to glaucoma, and more particularly to a mouse model of a VE-PTPlacZ mice bred to a Tie2 haploinsufficient mice and the use of VE-PTP inhibition for neuroprotection of glaucoma symptoms of elevated intraocular pressure. There is a method of producing a mouse model through deletion of a single PTPRB allele in a Tek haploinsufficient mouse. Further, the use of VE-PTP inhibition in the limbal vascular plexus provides neuroprotection from glaucoma symptoms of elevated intraocular pressure.

Abstract: This invention relates to the production and genotyping of mice lacking both Angiopoietin 1 and Angiopoietin 2. This invention also relates to the use of Tie2 receptor activation for treatment of open angle glaucoma, congenital glaucoma and cystic kidney disease, and more specifically to the use of angiopoietin 1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and Tie2-peptomimetics to improve lymphatic drainage in the Schlemm's canal and corneal limbal lymphatic system for open angle glaucoma and congenital glaucoma patients, and to slow and/or reduce the growth of cysts in patients with cystic kidney disease.

Abstract: This invention relates to the production and genotyping of mice lacking both Angiopoietin 1 and Angiopoietin 2. This invention also relates to the use of Tie2 receptor activation for treatment of open angle glaucoma, congenital glaucoma and cystic kidney disease, and more specifically to the use of angiopoietin 1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and Tie2- peptomimetics to improve lymphatic drainage in the Schlemm's canal and corneal limbal lymphatic system for open angle glaucoma and congenital glaucoma patients, and to slow and/or reduce the growth of cysts in patients with cystic kidney disease.

Abstract: This invention relates to the production and genotyping of mice lacking both Angiopoietin 1 and Angiopoietin 2. This invention also relates to the use of Tie2 receptor activation for treatment of open angle glaucoma, congenital glaucoma and cystic kidney disease, and more specifically to the use of angiopoietin 1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and Tie2— peptomimetics to improve lymphatic drainage in the Schlemm's canal and corneal limbal lymphatic system for open angle glaucoma and congenital glaucoma patients, and to slow and/or reduce the growth of cysts in patients with cystic kidney disease.

Abstract: The present invention relates to a vector construct, and more specifically to a vector construct comprising human hypoxia inducible factor ? gene. The present invention also relates to a transgenic animal or cell containing said vector construct which in the presence of an inducing agent expresses human hypoxia inducible factor ? gene causing hair growth suppression. The present invention further relates to use of this animal model for determining the efficacy of methods for suppressing or inducing hair growth and discover further molecules which regulate hair growth.

Abstract: The present invention relates to a vector construct, and more specifically to a vector construct comprising human hypoxia inducible factor ? gene. The present invention also relates to a transgenic animal or cell containing said vector construct which in the presence of an inducing agent expresses human hypoxia inducible factor ? gene causing hair growth suppression. The present invention further relates to use of this animal model for determining the efficacy of methods for suppressing or inducing hair growth and discover further molecules which regulate hair growth.